USP33
From Wikipedia, the free encyclopedia
Ubiquitin specific peptidase 33
|
||||||||||||||
PDB rendering based on 2uzg. | ||||||||||||||
Available structures: 2uzg | ||||||||||||||
Identifiers | ||||||||||||||
Symbol(s) | USP33; KIAA1097; MGC16868; VDU1 | |||||||||||||
External IDs | MGI: 2159711 HomoloGene: 8996 | |||||||||||||
|
||||||||||||||
RNA expression pattern | ||||||||||||||
Orthologs | ||||||||||||||
Human | Mouse | |||||||||||||
Entrez | 23032 | 170822 | ||||||||||||
Ensembl | ENSG00000077254 | ENSMUSG00000025437 | ||||||||||||
Uniprot | Q8TEY7 | n/a | ||||||||||||
Refseq | NM_015017 (mRNA) NP_055832 (protein) |
NM_001076676 (mRNA) NP_001070144 (protein) |
||||||||||||
Location | Chr 1: 77.93 - 78 Mb | Chr 3: 152.28 - 152.33 Mb | ||||||||||||
Pubmed search | [1] | [2] |
Ubiquitin specific peptidase 33, also known as USP33, is a human gene.[1]
[edit] References
[edit] Further reading
- Puente XS, Sánchez LM, Overall CM, López-Otín C (2003). "Human and mouse proteases: a comparative genomic approach.". Nat. Rev. Genet. 4 (7): 544–58. doi: . PMID 12838346.
- Maruyama K, Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides.". Gene 138 (1-2): 171–4. PMID 8125298.
- Suzuki Y, Yoshitomo-Nakagawa K, Maruyama K, et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library.". Gene 200 (1-2): 149–56. PMID 9373149.
- Kikuno R, Nagase T, Ishikawa K, et al. (1999). "Prediction of the coding sequences of unidentified human genes. XIV. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro.". DNA Res. 6 (3): 197–205. PMID 10470851.
- Li Z, Na X, Wang D, et al. (2002). "Ubiquitination of a novel deubiquitinating enzyme requires direct binding to von Hippel-Lindau tumor suppressor protein.". J. Biol. Chem. 277 (7): 4656–62. doi: . PMID 11739384.
- Li Z, Wang D, Na X, et al. (2002). "Identification of a deubiquitinating enzyme subfamily as substrates of the von Hippel-Lindau tumor suppressor.". Biochem. Biophys. Res. Commun. 294 (3): 700–9. doi: . PMID 12056827.
- Strausberg RL, Feingold EA, Grouse LH, et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi: . PMID 12477932.
- Curcio-Morelli C, Zavacki AM, Christofollete M, et al. (2003). "Deubiquitination of type 2 iodothyronine deiodinase by von Hippel-Lindau protein-interacting deubiquitinating enzymes regulates thyroid hormone activation.". J. Clin. Invest. 112 (2): 189–96. doi: . PMID 12865408.
- Ota T, Suzuki Y, Nishikawa T, et al. (2004). "Complete sequencing and characterization of 21,243 full-length human cDNAs.". Nat. Genet. 36 (1): 40–5. doi: . PMID 14702039.
- Gerhard DS, Wagner L, Feingold EA, et al. (2004). "The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).". Genome Res. 14 (10B): 2121–7. doi: . PMID 15489334.
- Rual JF, Venkatesan K, Hao T, et al. (2005). "Towards a proteome-scale map of the human protein-protein interaction network.". Nature 437 (7062): 1173–8. doi: . PMID 16189514.
- Allen MD, Bycroft M (2007). "The solution structure of the ZnF UBP domain of USP33/VDU1.". Protein Sci. 16 (9): 2072–5. doi: . PMID 17766394.